KRAS and metastatic neoplasm: Interestingly, the metastatic tumor in the RL, which consistently responded to panitumumab and showed no mutation by Sanger sequencing, revealed multiple KRAS mutations, Q61Ht, G12A and G12R, with indices higher than the cut-off values.